Literature DB >> 26201341

IL28B, HCV core mutations, and hepatocellular carcinoma: does host genetic make-up shape viral evolution in response to immunity?

Luca Valenti1, Edoardo Pulixi2, Susanna La Spina2.   

Abstract

Mutations in the core sequence of the HCV genome have been reported to influence treatment response, fibrosis progression, and hepatocarcinogenesis in Asian patients with genotype-1 chronic hepatitis C (CHC). In this issue, Miura et al. report data consistent with a causal relationship between the R70 → Q70 core variant and hepatocellular carcinoma (HCC) risk in CHC genotype-1b patients, by the prospective evaluation of changes in the consensus sequence in the entire open reading frame between treatment failure and HCC development or end of follow-up, and validation of the initial findings in a confirmatory cohort. Furthermore, they observed an association between the IL28B genotype, which is believed to influence the immune response to viral infection, and the direction of time-dependent changes in core residue 70, with unfavorable IL28B genotypes linked to a preferential shift to the 70Q associated with HCC. Although this association needs to be validated in independent cohorts, and IL28B variants did not influence HCC risk, these results suggest that IL28B genotype might not only influence the behavior of the innate immune system in the presence of HCV genotype-1 infection but also shape the resultant viral evolution, with possible consequences on major clinical outcomes, such as HCC development, and treatment response.

Entities:  

Keywords:  Chronic hepatitis C; Core mutations; Hepatitis C virus genome; Hepatocellular carcinoma; IL28B; Interferon lambda; Steatosis

Year:  2011        PMID: 26201341     DOI: 10.1007/s12072-011-9327-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  29 in total

1.  Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

Authors:  Stella De Nicola; Alessio Aghemo; Maria Grazia Rumi; Enrico Galmozzi; Luca Valenti; Roberta Soffredini; Raffaele De Francesco; Gian Maria Prati; Roberta D'Ambrosio; Cristina Cheroni; Maria Francesca Donato; Massimo Colombo
Journal:  Hepatology       Date:  2012-01-03       Impact factor: 17.425

2.  Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.

Authors:  Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

3.  Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

Authors:  Masao Honda; Akito Sakai; Tatsuya Yamashita; Yasunari Nakamoto; Eishiro Mizukoshi; Yoshio Sakai; Taro Yamashita; Mikiko Nakamura; Takayoshi Shirasaki; Katsuhisa Horimoto; Yasuhito Tanaka; Katsushi Tokunaga; Masashi Mizokami; Shuichi Kaneko
Journal:  Gastroenterology       Date:  2010-04-29       Impact factor: 22.682

Review 4.  IL28B single nucleotide polymorphisms in the treatment of hepatitis C.

Authors:  Christian M Lange; Stefan Zeuzem
Journal:  J Hepatol       Date:  2011-03-25       Impact factor: 25.083

5.  Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

Authors:  Gioacchino Leandro; Alessandra Mangia; Jason Hui; Paolo Fabris; Laura Rubbia-Brandt; Guido Colloredo; Luigi E Adinolfi; Tarik Asselah; Julie R Jonsson; Antonina Smedile; Norah Terrault; Valerio Pazienza; Maria Teresa Giordani; Emiliano Giostra; Aurelio Sonzogni; Giuseppe Ruggiero; Patrick Marcellin; Elizabeth E Powell; Jacob George; Francesco Negro
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

6.  IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.

Authors:  Carlo Fabris; Edmondo Falleti; Annarosa Cussigh; Davide Bitetto; Elisabetta Fontanini; Sara Bignulin; Sara Cmet; Ezio Fornasiere; Elisa Fumolo; Stefano Fangazio; Andrea Cerutti; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  J Hepatol       Date:  2010-09-19       Impact factor: 25.083

7.  Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.

Authors:  Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Med Virol       Date:  2011-06       Impact factor: 2.327

8.  Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C.

Authors:  Mika Miura; Shinya Maekawa; Makoto Kadokura; Ryota Sueki; Kazuki Komase; Hiroko Shindo; Takako Ohmori; Asuka Kanayama; Kuniaki Shindo; Fumitake Amemiya; Yasuhiro Nakayama; Takatoshi Kitamura; Tomoyoshi Uetake; Taisuke Inoue; Minoru Sakamoto; Shunichi Okada; Nobuyuki Enomoto
Journal:  Hepatol Int       Date:  2011-08-17       Impact factor: 6.047

9.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

10.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.

Authors:  David L Thomas; Chloe L Thio; Maureen P Martin; Ying Qi; Dongliang Ge; Colm O'Huigin; Judith Kidd; Kenneth Kidd; Salim I Khakoo; Graeme Alexander; James J Goedert; Gregory D Kirk; Sharyne M Donfield; Hugo R Rosen; Leslie H Tobler; Michael P Busch; John G McHutchison; David B Goldstein; Mary Carrington
Journal:  Nature       Date:  2009-10-08       Impact factor: 49.962

View more
  3 in total

Review 1.  Hepatitis C virus genetic variability and evolution.

Authors:  Natalia Echeverría; Gonzalo Moratorio; Juan Cristina; Pilar Moreno
Journal:  World J Hepatol       Date:  2015-04-28

Review 2.  Hepatitis C virus: Promising discoveries and new treatments.

Authors:  Juliana Cristina Santiago Bastos; Marina Aiello Padilla; Leonardo Cardia Caserta; Noelle Miotto; Aline Gonzalez Vigani; Clarice Weis Arns
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

3.  Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.

Authors:  Paola Dongiovanni; Quentin M Anstee; Luca Valenti
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.